Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the
maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to
ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will
investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).